Who are Comparator: losartan +/- HCTZ's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azilsartan medoxomil and hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-losartan-hctz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Comparator: losartan +/- HCTZ — Competitive Intelligence Brief

Comparator: losartan +/- HCTZ (Comparator: losartan +/- HCTZ) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB) + thiazide diuretic combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker (ARB) + thiazide diuretic combination AT1 angiotensin II receptor; sodium-chloride cotransporter (HCTZ) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: losartan +/- HCTZ (Comparator: losartan +/- HCTZ) — Organon and Co. Losartan is an angiotensin II receptor antagonist that blocks vasoconstriction and aldosterone secretion to lower blood pressure; HCTZ is a thiazide diuretic that reduces fluid volume.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: losartan +/- HCTZ TARGET	Comparator: losartan +/- HCTZ	Organon and Co	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 angiotensin II receptor; sodium-chloride cotransporter (HCTZ)
Azilsartan medoxomil and hydrochlorothiazide	Azilsartan medoxomil and hydrochlorothiazide	Takeda	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) + thiazide diuretic combination class)

Organon and Co · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: losartan +/- HCTZ — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-losartan-hctz. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab